

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/679,258	10/07/2003	Francesco Orlandi	1240-25	3122
7590 12/28/2006 DANIEL P. BURKE, ESQ.			EXAMINER	
DANIEL P. BURKE & ASSOCIATES, PLLC			CLOW, LORI A	
Suite 131 300 Rabro Driv	/e		ART UNIT	PAPER NUMBER
Hauppauge, NY 11788			1631	
			MAIL DATE	DELIVERY MODE
			12/28/2006	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/679,258	ORLANDI ET AL.	
Examiner	Art Unit	
Lori A. Clow, Ph.D.	1631	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 27 November 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. Mar The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:  $\square$  The period for reply expires  $\underline{3}$  months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. Inno event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on \_\_\_\_\_. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): \_\_\_ 6. Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. Tor purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-38. Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. 

The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). \_\_\_\_\_ 13. Other: \_\_\_\_.

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments fail to overcome the outstanding rejection under 35 USC 103 for the reasons set forth in the previous Office Actions. Claims 1-38 remain rejected under 35 U.S.C. 103(a) as being unpatentable over US 6,573,103 B1 (Wald), further in view of Stempfle et al. (Pediatric Radiology (1999) Vol. 29, pages 682-688). Applicant argues that: 1. Stempfle et al. do not teach or suggest using BPD/OFD ratio during the first trimester of pregnancy. This is not persuasive. Even though Stempfle teaches measurements at 15-40 WG, Wald provides the teaching that measurements can be taken at the first trimester of pregnanacy, as was pointed out in the Office Action of 03/02/06 on page 6.

2. Wald does not suggest modifying the teaching of Stempfle. This is not persuasive as was set forth in previous Office Actions. See for

example, the Office Action of 03/02/06 at page 6 and the Office Action of 12/16/04 at page 9.

Joe A Clar Patent Edomine 12/21/06 AU 163/

3. Even the prior art of record does not suggest using the cephalic index to modify an individual patient's risk. This is not persuasive, as has been set forth. Wald in view of Stempfle make obvious the instant claims. See Office Action of 12/16/04 which discusses that Wald teaches risk determined by statistical analysis based upon reference data derived from existing or future studies.

2